1. Qualitative risk assessment of follicle stimulating hormone injectable products
- Author
-
Julian M. Jenkins, Raj Mathur, Helen Kendrew, Douglas Steinke, and Osman H Zarroug
- Subjects
Adult ,endocrine system ,Menotropins ,Reproductive Techniques, Assisted ,medicine.drug_class ,medicine.medical_treatment ,media_common.quotation_subject ,Pharmaceutical Science ,Physiology ,Fertility ,02 engineering and technology ,030226 pharmacology & pharmacy ,Risk Assessment ,Injections ,03 medical and health sciences ,Follicle-stimulating hormone ,0302 clinical medicine ,medicine ,Humans ,media_common ,Assisted reproductive technology ,business.industry ,Treatment regimen ,021001 nanoscience & nanotechnology ,Needle stick injury ,Female ,Follicle Stimulating Hormone, Human ,Menotropin ,Gonadotropin ,0210 nano-technology ,Risk assessment ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
Background: Gonadotropin injections for fertility treatment regimens are usually self-injected, typically over 8 to 12 days during the assisted reproductive technology cycle. Parenteral gonadotropins are available in different formulations and administered through various systems. A user experience study and risk assessment were performed to evaluate different product types for risks to the patient when preparing and administering injections.Methods: Nine women of child-bearing age each prepared and administered injections of six products representing single-and multidose vials of menotropin for reconstitution (Merional® and Menopur®), follicle stimulating hormone (FSH) reusable pen injectors with (Puregon®) and without cartridges (Gonal-f®), and single-use FSH pre-filled pens (Bemfola®). Risk assessments based on user feedback were made with reference to EU regulations for implementing practices for safe use of injectable products. Results: Products requiring reconstitution with diluent in glass ampoules were associated with medium risk for sharps injury and a lower level of user confidence. Pen injectors were considered easy-to-use, with a low risk of sharps injury. Single-use pens were associated with the lowest risk of dosing errors.Conclusions: The study identifies differences in the risks for both sharps injuries and dosing errors between FSH delivery options that practitioners should consider when making a treatment choice.
- Published
- 2020
- Full Text
- View/download PDF